SAGE-547

DRUG6 trials

Sponsors

Supernus Pharmaceuticals, Inc., Sage Therapeutics

Conditions

Essential TremorPostpartum DepressionSevere Postpartum DepressionSuper-Refractory Status EpilepticusSuper-refractory Status Epilepticus

Phase 1

Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

CompletedNCT02052739

Supernus Pharmaceuticals, Inc.Super-refractory Status Epilepticus

Start: 2014-03-21End: 2015-05-03Updated: 2025-09-15

Phase 2

Evaluate SAGE-547 in Participants With Essential Tremor

CompletedNCT02277106

Sage TherapeuticsEssential Tremor

Start: 2014-09-23End: 2015-08-14Updated: 2022-06-29

Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression

CompletedNCT02285504

Supernus Pharmaceuticals, Inc.Postpartum Depression

Start: 2015-01-07End: 2015-06-05Updated: 2025-09-15

A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

CompletedNCT02614547

Supernus Pharmaceuticals, Inc.Severe Postpartum Depression

Start: 2015-12-15End: 2016-06-22Updated: 2025-09-15

Phase 3

A Study With SAGE-547 for Super-Refractory Status Epilepticus

CompletedNCT02477618

Supernus Pharmaceuticals, Inc.Super-Refractory Status Epilepticus

Start: 2015-06-30End: 2017-08-11Updated: 2025-10-14

Unknown Phase

An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus

Supernus Pharmaceuticals, Inc.Super-Refractory Status Epilepticus

Updated: 2025-09-15

Related Papers

Brexanolone in Postpartum Depression: <i>Post Hoc</i> Analyses to Help Inform Clinical Decision-Making.

2020-11-1213 citations

Associations between commonly used patient-reported outcome tools in postpartum depression clinical practice and the Hamilton Rating Scale for Depression

Archives of Women s Mental Health2020-07-1410 citations

Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.

2017-06-12300 citations